Google
FHTX 株価分析 — Foghorn Therapeutics Inc (Healthcare >> Biotechnology)
FHTX に関するよくある質問
FHTXのROE（自己資本利益率）は？
Foghorn Therapeutics IncのROEは98.58%です。
FHTXの配当利回りは？
Foghorn Therapeutics Incの配当利回りは0.00%です。
FHTXの品質スコア（Quality Score）は？
当社のAIはFHTXの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
FHTXは今が買い時ですか？
当社AIのタイミングスコアは100点中96点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
FHTXはどのセクターに属しますか？
Foghorn Therapeutics IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
FHTX AI Analysis Summary
Our AI summary for FHTX: Foghorn Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 98.58%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 96/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 5.57
Price
0.69
(14.14%)
Day Change
|
|
|---|
FHTX, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 5.57 |
| PBV / Sector |
-3.75 / 5.21
|
| Earning Per Share | -1.46 |
| PE / Sector |
N/A / 21.00
|
| PEG or PE/Growth / Sector |
N/A / 1.11
|
| Average 1M Daily Value |
1.17 M
GREAT
|
| Average 1W Daily Value |
1.06 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
47% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-07 08:11:40 |
| Symbol | FHTX |
| Name | FOGHORN THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 58.71 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 286.52 / 9,672.56 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 99 Coolidge Avenue, Watertown, MA, United States, 02472
Phone: 617 586 3100
Website: https://foghorntx.com
Employees: 106
Sector: Healthcare >> Biotechnology
Description: Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
